Pitavastatin - results from phase III & IV

Atherosclerosis Supplements

Volumn 11, Issue 3, 2010, Pages 8-14

  Betteridge, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dyslipidaemia; Hypercholesterolaemia; Lipid lowering; Pitavastatin

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; PYRROLES; QUINOLINES; SIMVASTATIN;

EID: 78650547620     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(10)71064-3     Document Type: Article

References (16)

1. Ose L, Budinski D, Hounslow N, Arneson V Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25(11):2755-2764.
2. Ose L, Budinski D, Hounslow N, Arneson V Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010, 210(1):202-208.
3. NK-104 Pitavastatin Investigators' Brochure 2007, Kowa Company, Ltd., Tokyo, Japan.
4. Saito Y, Yamada N, Teramoto T, et al. A randomized, doubleblind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002, 162(2):373-379.
5. Budinski D, Arneson V, Hounslow N, Gratsiansky N Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4(3):291-302.
6. Stender S, Hounslow N Robust efficacy of pitavastatin and comparable safety to pravastatin. Atheroscler 2009, 10(Suppl (2)):P770.
7. Hounslow NJ, Budinski D, Eriksson M. Pitavastatin 4 mg shows comparable LDL-cholesterol and superior triglyceride reduction to simvastatin 40 mg in high risk primary hypercholesterolemia or combined dyslipidaemia. EAS poster 2010.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
9. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl 2):S1-113.
10. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44(3):720-732.
11. Catapano AL Pitavastatin - pharmacological profile from early phase studies. Atheroscl Suppl 2010, 11(3):3-7.
12. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007, 24(5):429-440.
13. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201(2):345-352.
14. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008, 30(6):1089-1101.
15. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y A large-scale, long-term prospective post-marketing surveillance of pitavastatin (Livalo) - Livalo effectiveness and safety study (LIVES). Jpn Pharmacol Ther 2008, 36(8):709-731.
16. Teramoto T, Sasaki J, Ueshima H, et al. Goals of dyslipidemia management. J Atheroscler Thromb 2007, 14(5):209-212.